Ac Immune Sa (ACIU) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACIU Annual Cash Flow →
Quarterly cash flow trends provide additional context on Ac Immune Sa's liquidity and ability to support ongoing operations and capital needs.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
0 0 0 (Dec 31 2024)
Operating Activities
Income-88.17
Depreciation & amortization1.39
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Gain Loss On Disposals PropertyPlant And Equipment-0.02
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction2.59
Adjustments For Depreciation Expense Right Of Use Assets-
Adjustments For Finance Income Cost-
Adjustments For Sharebased Payments-
Adjustments For Increase Decrease In Employee Benefit Liabilities-
Adjustments For Interest Expense-
Adjustments For Decrease Increase In Other Operating Receivables-
Adjustments For Increase Decrease In Accrued Expenses-
Adjustments For Increase Decrease In Deferred Income-
Adjustments For Increase Decrease Long Term Financial Liabilities-
Adjustments For Increase Decrease In Trade Account Payable-
Finance Income Received Classified As Operating Activities-
Finance Costs Paid Classified As Operating Activities-
Adjustments For Decrease Increase In Accrued Income Including Contract Assets-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-74.28
Discontinued operations0.00
Net Cash flow from Operating Activities-175.52
Investing Activities
Capital Expenditures-0.90
Sale of Capital Items0.02
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Advances For Rent Deposit-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net64.60
Discontinued operations0.00
Net Cash Flow from Investing Activities79.53
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.02
Proceeds From Issue Of Convertible Debt-
Payments For Share Issue Costs-
Proceeds From Issuing Shares Net Of Underwriting Fees-
Payments For Share Issue Costs On Public Offering-
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.02
Effect of exchange rate on cash flow-6.74
Discontinued operations0.00
Free Cash Flow-176.41
Total Cash Flow36.28
4 historic quarters locked

Sign in to unlock the full Ac Immune Sa cash flow history.

About Ac Immune Sa Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-027342

Figures are derived from filed reports and may be restated. Historical data is subject to revision.